Pipeline strategy: Measuring the return from pharmaceutical innovation
Return on investment in biopharmaceutical R&D has increased for the second consecutive year, to 5.9%, driven by a surge in high-value products entering the late-stage pipeline. However, this progress appears fragile as rising R&D costs continue to pose a challenge to sustainable R&D. We’ll discuss: A bold approach that may be needed to continue uptick...

